WAYNE, PA — Palvella Therapeutics Inc. (Nasdaq: PVLA) recently appointed Jennifer J. McDonough as senior vice president of market access and patient services as the company prepares for a potential U.S. product launch, the company announced.
McDonough will oversee payer engagement, patient support, specialty distribution, and access strategy for Palvella’s QTORIN programs targeting rare skin diseases and vascular malformations.
She previously served as senior vice president of patient access, analytics, and operations at Krystal Biotech, where she supported the U.S. launch of VYJUVEK following its 2023 approval and growth to $389 million in annual sales by 2025.
McDonough has more than 25 years of experience in market access, reimbursement, and commercialization of rare disease therapies, including leadership roles at Strongbridge Biopharma, Cencora, EMD Serono, and CVS Health.
Palvella is developing QTORIN rapamycin for microcystic lymphatic malformations and other rare conditions, with a potential U.S. launch under consideration pending regulatory review.
“I am passionate about ensuring that QTORIN rapamycin reaches patients quickly and efficiently,” McDonough said.
For the latest news on everything happening in Chester County and the surrounding area, be sure to follow MyChesCo on Google News and MSN.